Has Farrukh Adhami, MD received payments from drug or device companies?

Yes. Drug and device makers reported $34,691 in general payments to Farrukh Adhami, MD across 623 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Farrukh Adhami, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Farrukh Adhami, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Farrukh Adhami, MD

Medical Oncology · Fort Wayne, INNPI 1598766925

Payments from drug & device makers

$34,691in general payments, 2019–2025

Across 623 payments — averaging $55.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Cornerstone Specialty Network LLC$18K
Johnson & Johnson$2K
Novartis$2K
Seagen Inc.$1K
Merck$1K
E.r. Squibb & Sons, L.L.C.$1K
plus $9K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Cornerstone Specialty Network LLC	22	$18,428
Johnson & Johnson(2 entities)	53	$1,718
Novartis	59	$1,531
Seagen Inc.	9	$1,377
Merck	75	$1,172
E.r. Squibb & Sons, L.L.C.	34	$1,066
Pfizer	40	$963
Daiichi Sankyo Inc.	17	$701
AstraZeneca(2 entities)	14	$636
Sanofi	23	$542
Gilead(2 entities)	16	$516
Amgen	26	$516
Genentech USA, Inc.	22	$476
Regeneron Healthcare Solutions, Inc.	16	$389
Pharmacyclics LLC, An Abbvie Company	21	$385
Sobi, Inc	16	$304
Eisai Inc.	16	$278
Takeda Pharmaceuticals U.S.A., Inc.	7	$267
Bristol Myers Squibb	13	$257
Verastem, Inc.	2	$242
AVEO Pharmaceuticals, Inc.	8	$242
Incyte Corporation	12	$223
Karyopharm Therapeutics Inc.	6	$223
AbbVie	9	$174
GSK	4	$173
Rigel Pharmaceuticals, Inc.	6	$172
Foundation Medicine, Inc.	4	$156
Beigene USA, Inc.	2	$131
ADC Therapeutics America, Inc.	1	$110
Exelixis Inc.	6	$103
Boehringer Ingelheim	5	$97
Array Biopharma Inc	7	$92
Stemline Therapeutics Inc.	1	$84
Ipsen Biopharmaceuticals, Inc	3	$74
Jazz Pharmaceuticals Inc.	4	$69
Legend Biotech USA Inc.	3	$67
Genmab U.S., Inc.	2	$50
Bayer	3	$50
Deciphera Pharmaceuticals Inc.	3	$49
Alnylam Pharmaceuticals Inc.	2	$40
Lilly USA, LLC	2	$38
EMD Serono, Inc.	2	$33
Blueprint Medicines Corporation	2	$32
Syndax Pharmaceuticals, Inc.	1	$32
Pharmaessentia USA Corporation	2	$30
Acrotech Biopharma Inc.	2	$30
Morphosys, US Inc.	2	$30
Adaptive Biotechnologies Corporation	1	$26
Caris MPI, Inc.	1	$23
Coherus Oncology, Inc.	1	$23
Pharming Healthcare, Inc.	1	$22
Sun Pharmaceutical Industries Inc.	1	$22
Fennec Pharmaceuticals, Inc.	1	$22
Acceleron Pharma, Inc.	1	$21
Aadi Bioscience, Inc.	1	$19
Dova Pharmaceuticals	1	$18
Tersera Therapeutics LLC	1	$18
Epizyme, Inc.	1	$17
Agios Pharmaceuticals, Inc.	1	$17
Sanofi-aventis U.S. LLC	1	$17

How this compares

$34,691 in reported general payments places this provider in the 60th percentile of 67 medical oncology providers in Indiana.

See all medical oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$1,644,099

Medicare patients

456

Services billed

103,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Fort Wayne

Sunil BabuFort Wayne$12.5M
Takefumi KomiyaFort Wayne$2.8M
Sushil JainFort Wayne$366K
Bert OneilIndianapolis$7.6M
Natraj AmmakkanavarIndianapolis$4.1M
Nasser HannaIndianapolis$2M
Costantine AlbanyLafayette$1.1M
Bolanle AdepojuGoshen$1M
Vijaya KakaniLafayette$942K
Pablo BedanoIndianapolis$886K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →